TRAIL Receptor-1/DR4 and TRAIL Receptor-2/DR5 belong to the TNFR superfamily of transmembrane proteins and contain a cytoplasmic death domain, which can activate the cells apoptotic machinery. These receptors are activated by binding to wither membrane anchored or soluble TRAIL/Apo2L. Recombinant human soluble TRAIL Receptor-1/DR4 is a 22.7 kDa protein (216 amino acid residues) consisting of the TNFR homologous, cysteine rich portion of the extracellular domain.
Human TNFRSF10A expressed in E.coli
CAT# CSC-CTK0335-50 (50 μg); CAT# CSC-CTK0335-250 (250 μg)
Greater than 98% as determined by SDS-PAGE and HPLC analysis.
Measured by its ability to inhibit apoptosis in LN-18 cells. The expected ED50 for this effect is 0.4 -0.5 μg/ml.
Less than 1 EU/μg.
The sterile-filtered solution was lyophilized with no additives.
Please centrifuge product briefly before opening the vial. Reconstitute in sterile, ultra-pure water to a concentration of 0.1 - 1.0 mg/ml. This solution can be diluted into other aqueous buffers and stored at -20°C for future use.
Storage & Stability
The lyophilized powder, though stable at room temperature for up to 3 weeks, is best stored desiccated at -20°C. Reconstituted sTRAIL Receptor-1 should be used immediately or stored in undiluted working aliquots at -20°C. Avoid repeated freeze / thaw cycles.
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon.